Pericardial Mesothelioma
Primary pericardial mesothelioma is an uncommon tumor of the mesothelial cells of the pericardium. It is, however, the most frequent primary pericardial neoplasm. As a pioneer in rare cardiovascular disease research enterprise, Protheragen is committed to offering all-around drug research and development services for such unmet medical needs, and providing a one-stop solution to pericardial mesothelioma.
Introduction to Pericardial Mesothelioma
Pericardial mesothelioma, an uncommon cancer of the double-walled sac that encompasses the heart. It is presumed to represent 2% to 4% of all cardiac and pericardial tumors and 0.3% to 1% of all mesotheliomas. Diagnosis of pericardial mesothelioma is challenging as the features are non-specific. Symptoms may include dyspnea, cough, edema, chest pain, features of constrictive pericarditis, cardiac tamponade, pericardial effusion with or without blood, and heart failure.

Pathogenesis of Pericardial Mesothelioma
Due to the rarity of pericardiac mesothelioma, the cause is difficult to identify; however, many etiologies are indicated as risk factors. In summary, 62% of the pericardial cases of mesothelioma are classified in the three categories of definitely, probably, or possibly exposed to asbestos in the occupational setting or other (domestic, environmental, or recreational) exposure. Hypothesized risk factors for pleural mesothelioma, including genetics, infections, and nutrition, are also discussed as possibly applicable to pericardial cases.

Therapeutics Development for Pericardial Mesothelioma
Drug Name | Mechanism of Action | Targets | Research Phase |
---|---|---|---|
Pemetrexed | Prevents the synthesis and repair of DNA. | Thymidylate synthase | Approved |
Cisplatin | Chemotherapy agents that contain platinum are used to cross-link DNA strands. | DNA | Approved |
Bevacizumab | Specifically targets VEGF, preventing the formation of new blood vessels required for tumor growth and metastasis. | VEGF | Approved |
Carboplatin | Functions by cross-linking DNA, which damages the genetic material of cancer cells, thus leading to their death. | DNA | Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen supports the entire process chain from early drug discovery to preclinical validation, including strong disease models that recapitulate the human disease and advanced preclinical research services. We cover diagnostics, therapeutics, disease modeling, and preclinical research for pericardial mesothelioma, contributing to an omnibus understanding and battle against this elusive disease. In addition, we offer key pharmacokinetics and drug safety studies as part of our complete range of services.
Therapeutic Development Services
Diverse Platforms

Animal Model Development for Pericardial Mesothelioma
Animal models are the most important tool to screen novel therapeutics, ranging from chemotherapy, targeted therapy, and immunotherapy, prior to human trials. At Protheragen, we realize the importance of high-quality animal models in preclinical studies and provide customized pericardial mesothelioma animal model development services to meet your specific research needs.

Induced models involve exposing animals, typically rodents, to carcinogenic agents known to cause mesothelioma in humans.
Optional models: Asbestos-induced model, etc.

These models involve manipulating the mouse genome to induce mesothelioma development, often by targeting tumor suppressor genes known to be inactivated in human mesothelioma.
Optional models: Cdkn2a+/-; Nf2+/- model, etc.
Pharmacokinetics and Drug Safety Research Services
When you choose Protheragen as your service provider for this project, you gain the help of an intensely experienced team with a cutting-edge facility dedicated to fighting against rare cardiovascular diseases. If you are seeking an experienced collaborator to assist your drug development journey in a rare cardiovascular disease, such as pericardial mesothelioma, please don't hesitate to get in touch to discuss and understand how we can help your research journey.
References
- Brydges, Hilliard et al. "Primary Pericardial Mesothelioma: A Population-Based Propensity Score-Matched Analysis." Seminars in thoracic and cardiovascular surgery 34.3 (2022): 1113-1119.
- Yan, Yibo et al. "Aggressive primary pericardial mesothelioma." European heart journal 45.6 (2024): 490.
For research use only, not for clinical use.